Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
LYRA THERAPEUTICS INC (LYRA) Stock Price & Overview
NASDAQ:LYRA • US55234L2043
Current stock price
0.495 USD
-0.82 (-62.5%)
At close:
0.35 USD
-0.15 (-29.29%)
After Hours:
The current stock price of LYRA is 0.495 USD. Today LYRA is down by -62.5%. In the past month the price decreased by -64.39%. In the past year, price decreased by -94.34%.
LYRA Key Statistics
52-Week Range0.4847 - 37.5
Current LYRA stock price positioned within its 52-week range.
1-Month Range0.4847 - 1.52
Current LYRA stock price positioned within its 1-month range.
- Market Cap
- 876.15K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -22.89
- Dividend Yield
- N/A
LYRA Stock Performance
Today
-62.5%
1 Week
-61.92%
1 Month
-64.39%
3 Months
-86.25%
Longer-term
6 Months -92.20%
1 Year -94.34%
2 Years -99.84%
3 Years -99.51%
5 Years -99.91%
10 Years N/A
LYRA Stock Chart
LYRA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LYRA. When comparing the yearly performance of all stocks, LYRA is a bad performer in the overall market: 99.48% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
LYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LYRA. Both the profitability and financial health of LYRA have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LYRA Earnings
On March 11, 2026 LYRA reported an EPS of -3.38 and a revenue of 25.00K. The company beat EPS expectations (36.94% surprise) and missed revenue expectations (-87.43% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateMar 11, 2026
PeriodQ3 / 2025
EPS Reported-$3.38
Revenue Reported25K
EPS Surprise 36.94%
Revenue Surprise -87.43%
LYRA Forecast & Estimates
6 analysts have analysed LYRA and the average price target is 16.32 USD. This implies a price increase of 3196.97% is expected in the next year compared to the current price of 0.495.
For the next year, analysts expect an EPS growth of 63.39% and a revenue growth -51.56% for LYRA
Analysts
Analysts43.33
Price Target16.32 (3196.97%)
EPS Next Y63.39%
Revenue Next Year-51.56%
LYRA Financial Highlights
Over the last trailing twelve months LYRA reported a non-GAAP Earnings per Share(EPS) of -22.89. The EPS increased by 69.28% compared to the year before.
Income Statements
Revenue(TTM)600.00K
Net Income(TTM)-32.95M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.38% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%62.44%
Sales Q2Q%-87.18%
EPS 1Y (TTM)69.28%
Revenue 1Y (TTM)-59.21%
LYRA Ownership
Ownership
Inst Owners21.14%
Shares1.77M
Float1.76M
Ins Owners0.01%
Short Float %0.21%
Short Ratio0.03
LYRA Industry Overview
LYRA operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
34%
Outperformed 34% of sub-industries
3 Month Rank
52%
Outperformed 52% of sub-industries
6 Month Rank
39%
Outperformed 39% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 3.7%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.9
- Average Debt/Equity
- 1.2
LYRA Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.68 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.99 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.46 | 269.662B | ||
| PFE | PFIZER INC | 8.85 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.44 | 123.709B | ||
| ZTS | ZOETIS INC | 16.17 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.58 | 28.899B | ||
| VTRS | VIATRIS INC | 6.02 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.49 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 34.34 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LYRA
Company Profile
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Company Info
IPO: 2020-05-01
LYRA THERAPEUTICS INC
480 Arsenal Way
Watertown MASSACHUSETTS 02472 US
CEO: Maria Palasis
Employees: 30
Phone: 16173734600
LYRA THERAPEUTICS INC / LYRA FAQ
What does LYRA do?
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Can you provide the latest stock price for LYRA THERAPEUTICS INC?
The current stock price of LYRA is 0.495 USD. The price decreased by -62.5% in the last trading session.
What is the dividend status of LYRA THERAPEUTICS INC?
LYRA does not pay a dividend.
What is the ChartMill rating of LYRA THERAPEUTICS INC stock?
LYRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for LYRA stock?
6 analysts have analysed LYRA and the average price target is 16.32 USD. This implies a price increase of 3196.97% is expected in the next year compared to the current price of 0.495.
What is the Price/Earnings (PE) ratio of LYRA THERAPEUTICS INC (LYRA)?
LYRA THERAPEUTICS INC (LYRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.89).
Should I buy LYRA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LYRA.